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We combined reverse and chemical genetics to iden-
tify targets and compounds modulating blood vessel
development. Through transcript profiling in mice, we
identified 150 potentially druggable microvessel-
enriched gene products. Orthologs of 50 of these
were knocked down in a reverse genetic screen in
zebrafish, demonstrating that 16 were necessary for
developmental angiogenesis. In parallel, 1280 phar-
macologically active compounds were screened in
a human cell-based assay, identifying 28 compounds
selectively inhibiting endothelial sprouting. Several
links were revealed between the results of the reverse
and chemical genetic screens, including the serine/
threonine (S/T) phosphatases ppp1ca, ppp1cc, and
ppp4c and an inhibitor of this gene family; Endothall.
Our results suggest that the combination of reverse
and chemical genetic screens, in vertebrates, is an
efficient strategy for the identification of drug targets
and compounds that modulate complex biological
systems, such as angiogenesis.
INTRODUCTION
Blood vessels allow for the efficient transportation of cells,
macromolecules, nutrients, and oxygen to peripheral tissues,432 Chemistry & Biology 16, 432–441, April 24, 2009 ª2009 Elsevierand for the removal of carbon dioxide and waste products.
Angiogenesis is the formation of new blood vessels from existing
ones and is an essential component of both physiological and
pathological tissue growth (Adams and Alitalo, 2007). Angiogen-
esis inhibitors have become important drugs in the treatment of
solid tumors and age-related macular degeneration (reviewed by
Andreoli and Miller [2007] and Ellis and Hicklin [2008]). Bevacizu-
mab (Avastin), a monoclonal antibody that neutralizes vascular
endothelial growth factor A (VEGF-A), was the first FDA-
approved therapy selectively targeting angiogenesis (Ferrara
et al., 2004). However, Bevacizumab and other angiogenesis
inhibitors have several drawbacks; they are only efficient in
combination with cytotoxic drugs, there are significant side
effects, and tumors may use alternate pathways to evade the
effect of VEGF-A blockade (Casanovas et al., 2005; Eskens
and Verweij, 2006; Ridgway et al., 2006; Zhu et al., 2007).
Thus, there is a need to identify additional angiogenesis targets
and develop improved antiangiogenic drugs. Several gene
products that are potential drug targets for antiangiogenic appli-
cations have been revealed by reverse and forward genetic
studies in mice and zebrafish (Adams and Alitalo, 2007; Cha
and Weinstein, 2007) . Additionally, chemical genetic screens
with in vitro cellular assays or in vivo screens in zebrafish have
been employed to identify drugs and drug-like compounds that
can modulate angiogenesis (Chan et al., 2002; Kwon, 2006;
Tran et al., 2007).
In order to identify genes, known drugs, and pharmacologi-
cally active compounds previously not implicated in angiogen-
esis modulation, we tested the feasibility of running parallelLtd All rights reserved
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Combination of Reverse and Chemical GeneticsFigure 1. Experimental Overview of the Parallel Reverse and
Chemical Genetic Screens
(A) The reverse genetic (RG) screen comprised 5856 genes derived from cDNA
libraries, constructed from pooled mouse vascular fragments isolated in vivo.
Vascular and corresponding nonvascular samples from various tissues and
stages were isolated and underwent RNA extraction, amplification, and
labeling. After mRNA expression profiling, 150 mouse genes were selected
for functional validation. Fifty mouse genes had suitable zebrafish orthologs,
and their functional importance in angiogenesis was evaluated by morpho-
lino-mediated knockdown in zebrafish embryos. Sixteen of the 50 knock-
downs resulted in vascular defects.
(B) In a separate chemical genetic (CG) screen, 1280 compounds were
screened in a human cellular angiogenesis assay. Ninety compounds inhibited
in vitro angiogenesis, and 28 of these, targeting 69 proteins, did not affect
fibroblast scattering. At the intersection of the two screens, three genes en-
coding members of the PPP1 and PPP2 families of S/T phophatases were
identified as angiogenesis targets.reverse genetic (RG) and chemical genetic (CG) screens, taking
advantage of several different vertebrate model systems. Our
hypothesis was that functionally important targets and pathways
will be conserved between species, and will therefore be repre-
sented in several different models. Thus, identification of over-
lapping gene products in the RG and CG screens would serve
to reduce the noise and possibly reflect drug targets and/or
pathways that are fundamental for angiogenesis.
We used transcript profiling in mice to identify 150 potentially
druggable microvessel-enriched gene products. Orthologs of
50 of these were identified and verified by using Ensembl or
the National Center for Biotechnology Information’s Homolo-
Gene and were knocked down in a RG screen in zebrafish,
demonstrating that 16 were necessary for developmental angio-
genesis. In parallel, we screened 1280 pharmacologically active
compounds in a human cell-based assay, identifying 28
compounds selectively inhibiting endothelial sprouting. The
mouse provided us with a well-studied mammalian system
with close homology to humans. The zebrafish offers severalChemistry & Biology 16advantages for RG screening of angiogenesis-modulating
genes, including its rapid development that can be followed non-
invasively over time. Lastly, as the goal is to develop compounds
for human targets and diseases, we used a human cell assay for
the CG screen.
Our results support the notion that the combination of RG and
CG screens, in vertebrates, is an efficient strategy for the identi-
fication of drug targets and compounds that modulate complex
biological systems, such as angiogenesis.
RESULTS
Reverse Genetic Screen for Novel Angiogenesis Targets
The first step when selecting genes for the RG screen was to
identify genes expressed in the vasculature, i.e., endothelial
cells, pericytes, and/or smooth muscle cells. We reasoned that
genes with high or selective expression in these cell types would
have an increased likelihood of being required for angiogenesis.
In addition, an enriched expression in the vasculature could
potentially make them specific angiogenesis targets with fewer
side effects. We identified vascular-enriched genes by mRNA
expression profiling of isolated vascular fragments as well as
nonvascular cells from developing and adult mouse tissues.
We chose to use mice because vascular fragments can be iso-
lated in sufficient quantities directly from the tissue with minimal
perturbation of gene expression, and close similarities exist
between the mouse and human genomes. Specifically, we
searched for genes that were (i) generally enriched in vascular
fragments; (ii) expressed in a particular vascular bed; and/or
(iii) expressed preferentially in either developing or adult vascula-
ture. The expression profiling was performed by using custom
cDNA arrays constructed from cDNA libraries from vascular
fragments. The array contained 12,554 EST clones, representing
5856 unique genes, and was estimated to cover approximately
half of the microvascular transcriptome. Importantly, genes
known to be expressed in the vasculature, such as the vascular
endothelial cadherin (ve-cadherin/cdh5) and endoglin, were
overexpressed in vascular preparations compared to nonvas-
cular cells (Figure 1; see Figures S1 and S2 available online).
Genes were selected for further analysis based on microvas-
cular-enriched expression, as determined by microarray experi-
ments; the presence of signal peptides and/or a transmembrane
motif, according to Ensembl annotation; druggability, as pre-
dicted by Gene Ontology annotation; and literature searches
(Figure S3; Tables S1 and S2). In summary, this resulted in the
selection of 150 mouse genes. Through comparison with a refer-
ence set of 58 genes with known selective expression in the
vasculature (Wallgard et al., 2008), we estimated that the selection
process resulted in a more than 20-fold enrichment of genes with
a vascular expression (Supplemental Experimental Procedures).
To assess gene function in a semi-high-throughput fashion, we
chose to knock down the gene products in zebrafish, by injection
of antisense morpholino oligonucleotides (MPOs). This approach
allowed for a rapid assessment of the requirements of these
genes during angiogenesis in a whole organism. First, zebrafish
orthologs of the selected genes were identified by using BLAST
searches of zebrafish cDNA and genomic sequence databases.
A total of 62 zebrafish orthologs representing 50 mouse genes
were identified with a sufficient 50 UTR sequence to allow for, 432–441, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 433
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Combination of Reverse and Chemical GeneticsTable 1. Gene Products Identified by mRNA Expression Profiling in Mice and Reverse Genetics in Zebrafish
mRNA Expression Profile Functional Validation
Gene Name Gene Ontology Molecular Function Vascular Selectivity Pref. Vasc. Bed Pref. Stage cdh5 ISH FITC-Dextran
alox5ap Enzyme activator activity Yes Skin - 0% 48%
ctsz Cysteine-type peptidase activity Yes - - 12% 19%
fzd6 G protein-coupled receptor activity Yes - - 21% 55%
gnb2l1 GTPase activity Yes - Embryo 12% 49%
hexb b-N-acetylhexosaminidase activity Yes Brain Adult 28% 58%
kiaa1274 Protein tyrosine phosphatase activity Yes Brain Embryo 10% 53%
p2ry5 Purinergic receptor activity, G protein
coupled
Yes Skin Adult 20% 24%
ppap2a Phosphatidate phosphatase activity Yes - Adult 48% 57%
ppih Cyclosporin A binding Yes Heart Embryo 3% 82%
ppp1ca Protein Ser/Thr phosphatase activity Yes - Embryo 0% 81%
ppp1cc Protein Ser/Thr phosphatase activity No Brain - 32% 44%
ppp4c Protein Ser/Thr phosphatase activity Yes Heart Embryo 18% 28%
rab11a GTPase activity Yes Heart Adult 0% 32%
rab5c GTPase activity Yes Skin - 0% 54%
ralb GTP binding Yes - Embryo 12% 84%
sat1 Diamine N-acetyltransferase activity Yes Heart Embryo 0% 43%
All gene names are for human genes. Vascular selectivity was defined as ‘‘Yes’’ or ‘‘No,’’ where ‘‘Yes’’ corresponded to upregulated (p < 0.05) signal
in one or more comparisons of vascular fragments against nonvascular tissues, and ‘‘No’’ corresponded to nonregulated signal in one or more
comparisons of vascular fragments against nonvascular tissues. Preferentially enriched expression in a vascular bed (Pref. Vasc. Bed) was defined
as upregulated (p < 0.05) signal in one vascular bed compared to another vascular bed. Significantly higher expression of a gene at embryonic or adult
stages was indicated as either preferred ‘‘Embryo’’ or ‘‘Adult.’’ The underlying data are presented in Table S2. cdh5 ISH, the percentage of zebrafish
embryos with aberrant cdh5 expression in the intersegmental vessels at 48–56 hpf, as detected by in situ hybridization. FITC-Dextran, the percentage
of zebrafish embryos with defective intersegmental vessels evident by FITC-dextran microangiography at 48–56 hpf. Details of reduced cdh5 staining
and/or FITC-dextran labeling are shown in Figure S4.the construction of suitable MPOs (Tables S2–S4). These 62
genes were knocked down in zebrafish embryos by microinjec-
tion of at least two different MPOs for each gene into 1-cell zebra-
fish embryos. To control for nonspecific effects as a result of
MPO injection, two nonoverlapping MPOs were used for each
gene. Dose-response experiments were carried out for each
MPO individually and in combination. In addition, injection of
a mixed-base MPO had no effect on vascular development,
even at a high dose (Figure 4). The zebrafish embryos were
analyzed at 24 and 56 hr postfertilization (hpf) for alterations in
vascular development. Selection criteria in the primary screen
comprised visually detectable defective blood flow and/or
reduced intersegmental vessel (ISV) sprouting detected as
reduced cdh5 staining in the vessels at 48–56 hpf. Knockdown
embryos exhibiting either of those changes were analyzed in
MPO dose-response studies and analyzed in detail for cdh5
mRNA expression at 24 and 56 hpf by mRNA in situ hybridization.
The embryos were also subjected to microangiography by using
fluorescent dextran injection at 48–56 hpf. Heart beat was moni-
tored to exclude heart dysfunction as an explanation for reduced
vascular perfusion. Sixteen genes exhibited significant dose-
dependent vascular defects in response to both injected MPOs
(Table 1; Figure S4; Table S5). For one of them, rab5c, vascular
leakage was also detected as extravasation of fluorescent
dextran (Figure S4I). Interestingly, several phosphatases were
identified in the RG screen. Three of the 16 genes were S/T phos-
patases (ppp1ca, ppp1cc, and ppp4), and one was a predicted
tyrosine phosphatase (kiaa1274, mouse ortholog x99384).434 Chemistry & Biology 16, 432–441, April 24, 2009 ª2009 ElsevieWe performed mRNA in situ hybridization on mouse embryo
tissue to validate the gene expression of the 16 genes identified
in the RG screen. Four out of 16 genes were selectively expressed
in vascular cells: sat1, ppap2a, x99384, and fzd6 (Figures 2A–2D;
Figure S5 [Visel et al., 2004]). The other 12 genes, including 3 S/T
protein phosphatases, ppp1ca, ppp1cc, and ppp4c, were over-
expressed in vascular cells, but were also expressed in other
cell types (Figures 2E–2G, and data not shown).
Chemical Genetic Screen for Novel Angiogenesis
Drugs and Targets
We screened 1280 well-characterized compounds from the
List of Pharmacologically Active Compounds (LOPAC1280) in
a cellular angiogenesis assay (Korff and Augustin, 1998). We
chose this chemical library, as the compounds have partially, to
extensively, characterized targets. The assay evaluates the effect
of compounds on angiogenic sprouting of human umbilical vein
endothelial cells (HUVECs), stimulated with VEGF-A in a three-
dimensional collagen type I matrix (Figures S6A–S6D). The effect
was determined as percentages of the positive VEGF-A control,
which was set to 100%. In the primary screen, 90 inhibitory
compounds were identified via microscope observation by two
independent observers. These compounds were rescreened,
and their inhibitory effects on sprouting were quantified. To
assess endothelial selectivity, the set of 90 compounds were
subsequently assayed for their effects on fibroblast scattering
by using normal human dermal fibroblasts (NHDFs). Twenty-
eight compounds, known to interact with 69 targets, showedr Ltd All rights reserved
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Combination of Reverse and Chemical GeneticsFigure 2. Validation of Vascular Expression
of Gene Products Identified in the Reverse
Genetic Screen
(A–G) Gene expression determined by nonradio-
active mRNA in situ hybridization (blue) on mouse
tissues. (A) sat1 expression was restricted to the
microvasculature in the heart at embryonic day
(E) 17.5. (B) Expression of sat1 in the vasculature
of kidney glomeruli (G) at E17.5. Arrows indicates
afferent and efferent arterioles. (C and D) At
E17.5, ppap2a was mainly expressed in large
vessels, here exemplified by two vessels in skel-
etal muscle (skeletal m.) and a vein (vein). (E–G)
The S/T protein phosphatases ppp1ca, ppp1cc,
and ppp4c were all expressed in the vasculature
as well as in other cell types. (E) Vascular ppp1ca
staining in the brain at E17.5 (arrowheads). (F)
Vascular expression of ppp1cc in the brain at
E14.5 (arrowheads). (G) Vascular expression of
ppp4c in skeletal muscle at E17.5 (arrowheads).
Scale bars represent 100 mm.significant inhibition of endothelial sprouting (<50% of VEGF-
A-induced sprouting), yet left fibroblast scattering relatively unaf-
fected (>50% of NHDF control scattering) (Figure 3; Table S6).
As expected, the screen identified compounds already known
to inhibit angiogenesis. For example,among the 90antiangiogenic
compounds we found the tyrosine kinase inhibitor SU5416, de-
signed to selectively inhibit VEGFR2 (Fong et al., 1999), and shown
by others to be antiangiogenic in zebrafish (Chan et al., 2002).
Furthermore, Nimesulide and b-Lapachone were among the 28
selective compounds. Nimesulide is a highly selective cyclooxy-
genase-2 inhibitor that belongs to a class of drugs known to inhibit
angiogenesis (Tsujii et al., 1998). b-Lapachone, a naphthoquinoneChemistry & Biology 16compound derived from the bark of the lapacho tree (Tabebuia
avellanedae), has been shown to have both antitumor activity
and antiangiogenic properties (Kung et al., 2007).
Reverse and Chemical Genetic Screens Identify
an Overlap of Pathways and Targets
In the sets of 16 genes and 28 compounds, we found several
regulators of prostaglandin/leukotriene synthesis, molecules
known to affect angiogenesis (reviewed by Romano and
Claria [2003]). For example, in the RG screen, we identified
ppap2a, which converts phosphatidic acid to diacylglycerol.
Diacylglycerol is, in turn, converted to arachidonic acid, theFigure 3. Twenty-Eight Compounds Inhibit VEGF-A-Induced HUVEC Sprouting Angiogenesis
VEGF-A-driven HUVEC angiogenesis was quantified as the average cumulative sprout length (black bars). The VEGF-A-driven sprouting was set to 100%,
and the basal sprouting in the absence of VEGF-A was set to 0%. The red line is a reference line for the basal HUVEC sprouting. Scattering of clustered NHDFs
in collagen gels in the presence of basal medium was set to 100% (gray bars). Twenty-eight compounds from the LOPAC library inhibited sprouting at > 50%
(black bars) and NHDF scattering at < 50% (gray bars)., 432–441, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 435
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Combination of Reverse and Chemical Geneticsprecursor of both prostaglandins and leukotrienes. Among the
16 targets of the RG screen was alox5ap, which converts arach-
idonic acid to hydroperoxyeicosatetraenoic acid (HPETE), the
immediate precursor of leukotriene A4. Furthermore, among
the 28 compounds identified in the CG screen, we discovered
two compounds inhibiting prostaglandin and leukotriene biosyn-
thesis: Nimesulide, which inhibits the synthesis of prostaglandin
from arachidonic acid, and Budesonide, which suppresses the
synthesis of both prostaglandin and leukotrienes, via the gluco-
corticoid receptor (Figure S7).
In light of the identification of 3 S/T protein phosphatases in the
RG screen, it was striking that 1 of the 28 compounds, Endothall,
is known to inhibit S/T protein phosphatases. There are five
known gene families of S/T protein phosphatases: PPP1,
PPP2A, PPP3, PPP5, and PPP7 (Cohen, 2004). Endothall inhibits
members of the PPP1 and PPP2A families (Erdodi et al., 1995),
with PP1 being five times less sensitive than PP2A to Endothall
(Li et al., 1993). Out of the S/T protein phosphatases identified
in the RG screen, ppp1ca and ppp1cc belong to the PPP1 family,
and ppp4c belongs to the PPP2A family (Cohen et al., 2005;
Cohen, 2004). Thus, three genes that were identified in the RG
screen corresponded to two of the gene families identified in
the CG screen (Figure 1).
Figure 4. Knockdown of ppp1ca, ppp1cc, and ppp4c Results
in Defects in Endothelial Path Finding and Tubulogenesis
(A–L) Images are all lateral views of the trunk vasculature at 48–50 hpf. (A–C)
Control embryo injected with a mixed-base morpholino. (D–L) Embryos in-
jected with morpholinos against (D–F) ppp1ca, (G–I) ppp1cc, and (J–L)
ppp4c. Endothelial cells (shown with green fluorescence in [A], [D], [G], and
[J]) were identified by using the Tg(fli1:egfp)y1 line. Dorsal aortas are marked
with arrowheads, examples of perfused ISVs are marked with arrows, and
examples of nonperfused ISVs are labeled with asterisks. (D and J) The
ppp1ca and ppp4c knockdowns resulted in enlarged ISVs, whereas (G)
knockdown of ppp1cc resulted in excessive branching of the ISVs. (B) At
48–50 hpf, circulation as observed by microangiography was observed in
control injected embryos (mixed-base MPO) in the dorsal aorta, cardinal
vein, and ISVs. (E and K) Rhodamine-dextran dye (red) often entered the
ventral aspect of the ISVs in the ppp1ca and ppp4c knockdowns (a more
severely affected embryo is shown for ppp4c), but a circulatory loop was not
established. (H) The ppp1cc knockdown embryos showed either an absence
of circulation or thin vessels with reduced circulation. (C, F, I, and L) Merged
images of the embryos shown in the previous two panels.436 Chemistry & Biology 16, 432–441, April 24, 2009 ª2009 ElsevierThere were three other S/T phosphatase inhibitors present
among the 1280 compounds screened: the PPP1 and PPP2A
family inhibitors Cantharidin and Cantharidic acid (both struc-
tural analogs of Endothall), as well as Cyclosporin A (a PPP3-
family inhibitor). Cantharidin and Cantharidic acid were present
among the 90 identified antiangiogenic compounds. However,
at the screening concentration used, these compounds also
affected fibroblast scattering, and were thus excluded in the
process. Cyclosporin A had no effect on angiogenic sprouting
(data not shown), further suggesting specificity to the involve-
ment of PPP1 and PPP2A family members in angiogenesis.
Protein Phosphatases ppp1ca, ppp1cc,
and ppp4c Affect Vascular Perfusion
We next focused on the S/T protein phosphatases that overlap-
ped in the two screens. First, we performed a dose-response
titration of Endothall in the cellular angiogenesis assay. This
resulted in IC50 values for HUVECs and NHDFs of 0.25 mM and
1.2 mM, respectively, thus indicating that endothelial cells are
five-fold more sensitive to PPP1 and/or PPP2A inhibition than
NHFDs (Figures S6E and S6F). Second, to better characterize
the effects observed in the RG screen, we repeated the zebrafish
knockdown experiments with ppp1ca, ppp1cc, ppp4c, and
control MPOs in a transgenic line of zebrafish expressing green
fluorescent protein in endothelial cells, Tg(fli1:egfp)y1. These
transgenic embryos allowed us to follow endothelial migration
during embryonic vasculogenesis and angiogenesis. Subse-
quent formation of patent perfused vessels was assessed by
using microangiography at 48–50 hpf.
In all S/T protein phosphatase knockdowns, microangiography
revealed defects in perfusion (Figure 4; Table 2). The endothelial
cells that form the axial vasculature migrated to the midline, and
sprouting from this location to form the ISVs appeared to be
normal. However, in the most severely affected embryos of
ppp1cc knockdowns, the ISVs displayed excessive branching,
although the endothelial cells were able to migrate dorsally.
This path-finding phenotype is similar to the knockdowns of the
neuropilins in zebrafish (Martyn and Schulte-Merker, 2004). For
knockdown of ppp1ca and ppp4c, incomplete perfusion was
accompanied by a dilated or enlarged vessel diameter (J.J.E.,
unpublished data). Based on the phenotypes observed after
gene knockdown, the protein phosphatases ppp1ca, ppp1cc,
and ppp4c may thus have roles during both endothelial guidance
and tubulogenesis/perfusion. The PPP1 and PPP2A gene fami-
lies have many targets and have been implicated in numerous
cellular functions (reviewed by Cohen [2002, 2004] and Cohen
et al. [2005]). They are highly conserved and homologous, which
suggests a high degree of functional redundancy. However, the
vascular defects in otherwise overtly normal S/T protein phos-
phatase knockdown embryos indicate specific functions or
particular sensitivity to protein phosphatase-regulated signaling
in the vasculature.
Endothall Treatment of Zebrafish Phenocopies
the Knockdowns of ppp1ca, ppp1cc, and ppp4c
Next, we were interested to test whether treatment with Endo-
thall, the S/T phosphatase inhibitor identified in the chemical
screen, would result in similar phenotypes as the knockdowns
of the S/T protein phosphatases. Zebrafish embryos wereLtd All rights reserved
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Combination of Reverse and Chemical GeneticsTable 2. Analysis of Vascular Defects from the Knockdown of ppp1ca, ppp1cc, and ppp4c: Analysis by Microangiography
in the Tg(fli1:egfp)y1 Zebrafish Line
ISV Defects
Axial Vascular Defects ISV Defects in Total
Condition MPO Dose % n % n Low % Medium % High %
Control 2% 49 10% 43 0% 0% 10%
Control MPO 6 ng 0% 11 0% 11 0% 0% 0%
12 ng 0% 9 0% 9 0% 0% 0%
ppp1ca 12 ng 0% 10 50% 10 20% 10% 20%
ppp1cc 4.5 ng 7% 15 86% 14 50% 21% 14%a
9 ng 25% 12 89% 9 22% 44% 22%a
ppp4c 4 ng 48% 23 83% 12 8% 8% 67%
4 ng 7% 14 15% 13 15% 0% 0%
8 ng 60% 15 17% 6 0% 0% 17%
8 ng 0% 9 44% 9 33% 11% 0%
Tg(fli1:egfp)y1 embryos were injected with morpholinos against ppp1ca, ppp1cc, or ppp4c. Vascular development was scored at 48–50 hpf by exam-
ining circulation using microangiography and accessing endothelial migration after EGFP fluorescence. Axial vascular defects were scored as an
absence of circulation in the dorsal aorta and cardinal vein. These embryos could not be examined for circulation in the ISVs. Defects in the circulation
in the ISVs were scored as low (<30% affected), medium (30%–70% affected), or high (>70% affected).
a Pathfinding defects of the endothelial cells in the ISVs were observed after the knock down of ppp1cc in the highly affected class.soaked in different concentrations of Endothall, and treatment
was initiated at the 20-somite stage (equivalent to 20 hpf). During
this stage, the axial vessels in the trunk, the dorsal aortal, and
the cardinal vein form by vasculogenesis and begin tubulogene-
sis. Also, at the same time, the first wave of angiogenesis from
the dorsal aorta begins as endothelial cells migrate to form the
ISVs. Using a similar strategy as for the analysis of the knock-
down phenotypes described above (Figure 4), endothelial
migration during formation of the ISVs was followed in the
Tg(fli1:egfp)y1 transgenic embryos, and the emergence of patent
vessels was investigated by using microangiography at 48–50 hpf.
Similar to knockdowns of ppp1ca, ppp1cc, and ppp4, Endo-
thall treatment resulted in dose-dependent reduction of ISV
perfusion without strongly affecting endothelial migration
(Figure 5).
DISCUSSION
To our knowledge, this is the first systematic study combining
parallel RG and CG screens in vertebrates. CG screens are
powerful tools in research and drug discovery, but they are
hampered by the difficulty of identifying the targets of the effec-
tive compounds. In invertebrates, it has been shown that
a comparison between phenotypes resulting from RG and
compound screens in the same model system may reveal
targets or pathways affected by the compound. For example,
in Drosophila, phenotypic comparison showed that g-secretase
inhibitors target the NOTCH receptor, and in Caenorhabditis
elegans, Ezetimibe was shown to target the annexin2 pathway
(Ross-Macdonald, 2005). Moreover, the use of systematic RG
and CG screening in Drosophila has linked new drug-like
compounds to known pathways that control specific biological
processes, such as cytokinesis (Eggert et al., 2004). However,
from a drug development perspective, invertebrate model
systems have limitations both in the types of biological
processes that may be assayed, and in their relevance to humanChemistry & Biology 16disease. For example, limitations are apparent when diseases
that affect the vascular system are considered. Many of the
known signaling pathways in the vascular system of vertebrates
are not represented in invertebrates, nor are well-developed
circulatory systems. Our results suggest that parallel RG and
CG screens can be used, not only in invertebrates, but also in
more complex, and for human disease, more relevant vertebrate
systems, to identify candidate targets/pathways hit by to
compounds having an effect in chemical screens. Larger
screens and applications in other areas than angiogenesis are
clearly needed to validate whether the combination of RG and
CG screens in vertebrates commonly identify the same targets
and processes, but our study does suggest that this may very
well be the case.
The task of identifying the overlap of the screens was simpli-
fied because the targets of the compounds used in the CG
screen have previously been partly characterized. This is not
the case when large libraries containing new chemical entities are
tested. However, the fact that Endothall phenocopied the knock-
downs of ppp1ca, ppp1cc, and ppp4c, and that we identified key
components of the prostaglandin/leukotriene biosynthesis
pathway in both screens, suggest that detailed phenotypic
comparison of RG and CG screens can reveal which targets or
pathways are also affected by novel chemical entities.
Obviously, an important question is whether the assays score
for the same biological process. In the CG screen, the readout is
inhibition of endothelial sprouting, and in the RG screen we
screen for both angiogenesis and perfusion defects. In the CG
screen, we identified Endothall as a compound with inhibitory
effects on endothelial sprouting. However, when we knock
down the expression of its target genes, including ppp1ca,
ppp1cc, and ppp4cc, we primarily detect a defect in vascular
perfusion, but not in endothelial migration. We believe that the
underlying mechanism triggering the different outcomes might
be the same, but depending on the specific assay or model,
they will result in different phenotypes. This has been observed, 432–441, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 437
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example, the mouse knockout of vegfr2 results in early embry-
onic lethality due to a halt in vasculogenesis and angiogenesis
(Shalaby et al., 1995). However, the knockdown of vegfr2 in
zebrafish displays flow defects (Bahary et al., 2007). Importantly,
it is clear from both of these studies that vegfr2 has an important
role in blood vessel development. Needless to say, results from
a screen must be interpreted carefully, and more studies are
required to confirm and extend the analysis in order to mechanis-
tically understand the results of these initial findings.
The LOPAC set of 1280 compounds contained 4 S/T protein
phosphatase inhibitors in total. Three PPP1 and PPP2A inhibi-
tors, Cantharidin, Cantharidic acid, and Endothall, were among
the set of 90 antiangiogenic compounds identified. The fourth
inhibitor was Cyclosporin A, a PPP3-family inhibitor that was
not identified by the screens, suggesting that PPP1 and
PPP2A, but not PPP3, have roles in vascular development.
Cantharidin and Cantharidic acid were excluded from the final
hit list, not because they were not efficient antiangiogenic
compounds, but rather because they also had an inhibitory
effect on fibroblast scattering. Importantly, Cantharidin and Can-
tharidic acid are 10-fold more potent inhibitors of PPP1 and
PPP2A than Endothall. Thus, at the screening concentration
used, any selective sensitivity of HUVECs (compared to NHDFs)
to Cantharidin and Cantharidic acid is likely masked by the
potency of these compounds, enabling them to affect NHDFs
as well.
Figure 5. Treatment of Embryos with Endo-
thall Results in Defects in Tubulogenesis
(A, D, and G) Endothelial cells in the trunk were
analyzed for defects in migration in the Tg(fli1:
egfp)y1 line (green fluorescence) at 48–50 hpf. (B,
E, and H) Analysis of circulation defects by using
microangiography (rhodamine-dextran imaging,
red) at 48–50 hpf. (A–I) are lateral views of the
trunk. (A–C) Treatment with either carrier (DMSO
control) or (D–I) Endothall did not alter endothelial
migration (see Tg(fli1:egfp)y1 in [A], [D], and [G]). (B,
E, and H) Microangiography revealed defects is
circulation consistent with defects in tubulogene-
sis. Two classes of affected embryos are shown.
In weakly affected embryos (low effect), some of
the ISVs would fail to circulate rhodamine-dextran.
In more severely affected embryos (high effect),
most of the ISVs failed to transfer dye. (C, F, and
I) Merged images of the previous two panels.
Dorsal aortas are marked with arrowheads, exam-
ples of perfused ISVs are marked with arrows, and
examples of non-perfused ISVs are labeled with
asterisks. (J) Dose response to bathing embryos
in Endothall. Embryos were scored based on
circulation in the axial vessels and the ISVs as in
Table 2. Vascular collapse was observed with
the highest concentration of Endothall.
The PPP1/PPP2A inhibitor Endothall
and its structural analogs are compounds
with an inherent and increasing toxicity in
the following sequence: Endothall < Can-
tharidic acid < Cantharidin (Li et al.,
1993). In our experiments, in which zebrafish embryos were
treated with Endothall, the effective dose was close to the toxic
dose. This finding is supported by studies of Cantharidin in mice
by others (Eldridge and Casida, 1995; Wang, 1989). Neverthe-
less, there are several lines of evidence that suggest that
members of the PPP1 and PPP2 families have specific roles in
vascular formation. First, morpholino knockdowns of ppp1ca,
ppp1cc, and ppp4 are selective, and each results in vascular
defects in morphologically overtly normal embryos (Figure 4;
Figures S4K, S4L, and S4O). Second, the IC50 titration of Endo-
thall indicates that endothelial cells are more sensitive than
NHDFs. Third, the effect of Endothall on vascular perfusion in ze-
brafish was dose dependent and effective at a lower than toxic
dose. In summary, this argues for a primary role of the PPP1
and PPP2A families of S/T phosphatases in proper vascular
formation.
The fact that two independent screens identified S/T protein
phosphatases from the PPP1 and PPP2A families suggests
that these genes are critically involved in angiogenesis. Our find-
ings are strengthened by the fact that we arrive at the same
targets from screening approaches involving different species
and models. Future studies will address the mechanisms behind
the effects of the PPP1 and PPP2A families of S/T phosphatases
on blood vessels. Potential mechanisms for the PPP1 family
include modulation of vascular permeability, cytoskeletal struc-
ture, and filopodia extension. PPP2A has been implicated in
endothelial migration (Hartel et al., 2007; Li et al., 2007; Shinoki438 Chemistry & Biology 16, 432–441, April 24, 2009 ª2009 Elsevier Ltd All rights reserved
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dimethylanhydride of Endothall, has been shown to enhance
endothelial-mediated contraction of arteries and endothelial
permeability (Knapp et al., 1999, 2000). We thus note that the
cell biological roles of the PPP1 and PPP2A families, to a certain
extent, overlap those of VEGF-A, and we are currently investi-
gating the relationship of these genes to the VEGF pathway
(J.J.E., unpublished data). Another major signaling pathway in
vascular biology is TGF-b (reviewed by Gaengel et al. [2009]),
affecting many different steps in angiogenesis, including lumen
formation (Oh et al., 2000). It is therefore interesting that PP1a
determines the duration of TGF-b signaling (Valdimarsdottir
et al., 2006). Furthermore, the PPP1 and PPP2A inhibitor
Cantharidin, historically extracted from the blister beetle, Mylab-
ris phalerata, has been used in traditional medicine as an antitu-
moral substance for thousands of years. When tested in the
clinic, Cantharidin was shown to have beneficial effects against
primary hepatoma (Wang, 1989). It will be important to determine
the degree to which these effects on tumorigenesis are attribut-
able to the antiangiogenic properties of PPP1 and PPP2A inhib-
itors shown in this study.
SIGNIFICANCE
Inhibition of angiogenesis is an important mode of action for
several oncology drugs on the market, but there is still
a need to find newdrugs to obtain greater efficacy and fewer
side effects. We show that parallel reverse genetic (RG) and
chemical genetic (CG) screens complement each other and
facilitate target identification in angiogenesis. Thereby, we
identify 16 putative drug targets and 28 pharmacologically
active compounds, targeting 69 gene products, all with
angiogenesis-regulating properties. Importantly, we identify
an overlapping set of targets and pathways from the two
screening approaches. To our knowledge, this is the first
report describing the use of parallel RG and CG in verte-
brates to identify and validate drug targets and pathways.
EXPERIMENTAL PROCEDURES
RNA Preparation and cDNA Library Construction
Isolation of mouse microvascular fragments by using Dynabeads (Dynal,
Invitrogen) has been described previously (Bondjers et al., 2006). In this study,
microvascular fragments were isolated from adult brain and liver and from
embryonic (E16.5–18.5) brain, liver, and skin from wild-type, Tie-1 knockout,
PDGF-B knockout, and PDGF-Rb knockout embryos. Protocols were opti-
mized by using Tie2LacZ mice, a knockin mouse in which the endothelial cells
can be stained with X-Gal. Using RNeasy mini kits (QIAGEN), 300 mg vascular
total RNA was isolated. The RNA was used to produce a standard oligo-
dT-primed cDNA library (Soares et al., 1994) (custom synthesis by Incyte). In
addition, three normalized libraries were generated from the standard library
by using a modification of the technique described by Soares et al. (1994), in
which high-abundance transcripts were suppressed to different degrees. In
total, the four libraries comprised 16,000 cDNAs cloned into the pBluescript
vector and stored as bacterial clones. For descriptions of subsequent
sequence trimming and annotation, please see Supplemental Experimental
Procedures.
Microarray Data Generation
For a description of the production of spotted cDNA microarrays (the Angio
chip), please see Supplemental Experimental Procedures.Chemistry & Biology 16Mouse microvascular fragments and the corresponding nonvascular tissue
from embryonic (E18.5) heart and skin, adult brain, and adult heart were
prepared as previously described (Bondjers et al., 2006). After the separate
isolation of total RNA from these cell fractions, the RNA was amplified for
two rounds (Scheidl et al., 2002; Wang et al., 2000), in parallel with Universal
Mouse Reference RNA (Stratagene). Amplified sample RNA was labeled
with the fluorescent dye Cyanine-3 (Cy3) conjugated to UTP (Amersham-
Pharmacia, now GE Healthcare), and the Universal Mouse Reference was
labeled with Cyanine-5 (Cy5) conjugated to UTP. Cy3- and Cy5-labeled mate-
rials were simultaneously hybridized to the Angio chip, by using the DIG Easy
Hyb hybridization solution (Roche). Hybridizations were performed in a water
bath for 1.5 hr at 44C, instantly followed by 15–20 hr at 40C. Hybridized
microarrays were washed and thereafter scanned by using a dual laser
scanner (GenePix 4000B, Axon). Raw data were extracted by using ImaGene
(BioDiscovery) and were processed and normalized with the LOESS method
by using the Bioconductor Limma Package (version 2.9.11, www.
bioconductor.org).
Mouse mRNA In Situ Hybridization
Nonradioactive mRNA in situ hybridization was performed on 14 mm thick
sections with digoxygenin-labeled RNA probes (Boehringer Ingelheim) visual-
ized by alkaline phosphatase-conjugated antidigoxygenin antibodies, as
described previously (Bostrom et al., 1996). Antisense and sense probes for
the investigated genes were generated from the corresponding EST clones
of the vascular cDNA libraries through restriction, followed by transcription,
with T7 and T3 RNA polymerases.
Zebrafish Experiments
Morpholino design and injection were carried out as described (Nasevicius
and Ekker, 2000). For each gene, two nonoverlapping morpholinos were
designed against the 50UTR to the first 25 bp of coding sequence and injected
individually and together. When two zebrafish orthologs were found that cor-
responded to one mouse gene, the overlapping requirements of both genes
during vascular development were tested in double knockdown experiments.
In situ hybridization with cdh5 was conducted as described (Larson et al.,
2004) with 40 embryos that were coinjected with two morpholinos. Morpho-
lino doses that resulted in severe cell death were avoided (Ekker, 2000). To
control for nonspecific effects as a result of MPO injection, two nonoverlapping
MPOs were used for each gene, and dose-response curves were carried out
for each MPO individually and in combination. Forty-six of the genes targeted
with MPOs had little or no effect on vascular development, suggesting
specificity for the 16 genes we identified as being required for vascular devel-
opment. In addition, injection of a mixed-base MPO had no effect on vascular
development, even at a high dose. Microangiography was performed by using
FITC or rhodamine-dextran injection into the sinus venosus (Nasevicius and
Ekker, 2000). Both in situ hybridization and microangiography experiments
were scored by examining endothelial migration and circulation in the interse-
gemental vessels.
For injection experiments, 3 ml of a solution containing Endothall in 0.5%
DMSO was injected directly into the yolk of dechorionated 20-somite-stage
Tg(fli1:egfp)y1 embryos. For bathing experiments, dechorionated embryos
were incubated with different concentrations of Endothall in fish water contain-
ing 0.5% DMSO. Embryos were raised to 48–50 hpf in plastic petridishes with
a 1% agarose pad. Microangiography was performed by injection of 2–5 ml
5 mg/ml rhodamine-dextran (1,000,000 MW, Invitrogen). Fluorescence was
observed on a Zeiss Discovery dissection scope. Vascular defects were cate-
gorized as normal, low (i.e., <30% absence of intersegmental vessel staining
or FITC-dextran signal), Medium (i.e., 31%–70% defective intersegmental
vessel staining/signal), or high (i.e., >70% defective intersegmental vessel
staining/signal).
Chemical Genetic Screen
LOPAC1280 (Library of Pharmacologically Active Compounds) is a collection of
chemical compounds that contains marketed drugs, failed development
candidates, and ‘‘gold standards’’ that have well-characterized activities
(Sigma-Aldrich, Inc.). The LOPAC compounds were tested at a concentration
of 10 mM to evaluate their potential to inhibit VEGF-stimulated sprouting of
endothelial cells clustered in a three-dimensional gel. Test substances were, 432–441, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 439
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diluted to a 10-fold concentrated working solution (100 mM) in endothelial
cell basal medium with 25 ng VEGF/100 ml for the stimulation of HUVEC sprout-
ing or without VEGF for assaying fibroblasts.
Compounds were tested as described by Korff and Augustin (1999). In brief,
spheroids were prepared by pipetting 500 cells (HUVEC, PromoCell, Heidel-
berg, Germany) or fibroblasts (NHDF, PromoCell) in a hanging drop on plastic
dishes to allow for overnight spheroidal aggregation. Spheroids were harvested,
and 50 spheroids were seeded in a solution of 900 ml methocel-collagen and
pipetted into individual wells of a 24-well plate to allow collagen gel polymeriza-
tion. Samples were added after 30 min by pipetting 100 ml of a 10-fold concen-
trated working dilution of the test substances on top of the gel. Plates were
incubated at 37C for 24 hr. Dishes were fixed at the end of the experimental
incubation period by the addition of 1 ml 10% paraformaldehyde.
In the primary screen, the sprouting intensity of endothelial cells was
assayed microscopically by two independent investigators. In a rescreen,
the sprouting intensity of endothelial cells and fibroblasts was quantified by
a semiautomated image-analysis system. The cumulative sprout length per
spheroid was determined by using an Olympus IX50 inverted microscope
and the digital imaging software analySIS (Soft Imaging System, Mu¨nster,
Germany). The mean of the cumulative sprout length of ten randomly selected
spheroids in each well was analyzed and used as an individual data point. The
reductions in angiogenic sprout length were expressed as percentages of the
positive VEGF-A control, which was set to index 100. For each plate, baseline
control sprouting was measured and subtracted from the measured value of
sprout length to ensure valid measurement of VEGF-A-induced sprouting.
Thus, the reduction of sprout length (percentage of VEGF-A-induced control)
may occasionally give values below zero. The inhibitors were classified
according to the following: category 1, inhibition of VEGF-induced HUVEC
sprouting (<80% of control sprouting), with a limited effect on fibroblast scat-
tering (>50% of control); category 2, HUVEC sprouting < 50% of control, and
fibroblast scattering > 50% of control; category 3, HUVEC sprouting < 50% of
control, and fibroblast scattering < 50%; category 4, HUVEC sprouting > 50%
of control. A cutoff was set at category 2; thus, only compounds in categories
1 and 2 were included in the list of the 28 selective antiangiogenic compounds.
The HUVEC spheroids display minor sprouting activity without the presence of
VEGF-A (Figure 4A), which represents the baseline.
Statistical Analysis
At least three biological replicates were used for every cell fraction (e.g., adult
brain EC) tested. RNA was isolated from all cell fractions, and each sample was
subsequently used for one individual microarray hybridization. The average
expression value was calculated for each gene in every sample group (e.g.,
adult heart EC or embryonic heart EC). The fold change of each gene between
the two sample groups was calculated as the ratio between the two averages.
To assess the significance of differential expression, a Student’s t test was
performed on each gene to obtain the raw p value (two-sided, equal variance)
(Cui and Churchill, 2003). Multiple test correction of raw p values was done by
using the false discovery rate method (Hochberg, 1995). The calculation was
performed by using the stats package in R (version 2.4.1, www.r-project.
org). Genes with a raw p value % 0.05 and a log2 ratio R 0.3 or % 0.3
were considered as significantly regulated.
For the chemical genetic screen, the average sprout length was determined
and the confidence interval was calculated at the a level of 0.05. All selected
compounds inhibited sprouting by more than 50% of control when using
HUVEC spheroids (p < 0.05), but less than 50% of control when using NHDF
spheroids (p < 0.05).
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